Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cafelkibart plus Toripalimab in Advanced MSI-H/dMMR Solid Tumors
NCT06873854Phase 2Not yet recruiting
- Sponsor
- LaNova Medicines
- Start
- Mar 2025
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LM-108 in solid tumor, sponsored by LaNova Medicines. Primary endpoint: Overall Response Rate at 104 weeks. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
LM-108
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06873854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06873854.